In the past week, EBS stock has gone down by -3.05%, with a monthly gain of 69.47% and a quarterly surge of 437.50%. The volatility ratio for the week is 10.30%, and the volatility levels for the last 30 days are 10.15% for Emergent Biosolutions Inc The simple moving average for the last 20 days is 25.09% for EBS stock, with a simple moving average of 218.62% for the last 200 days.
Is It Worth Investing in Emergent Biosolutions Inc (NYSE: EBS) Right Now?
The stock has a 36-month beta value of 1.61. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EBS is 50.20M, and at present, short sellers hold a 10.35% of that float. On July 22, 2024, the average trading volume of EBS was 5.33M shares.
EBS) stock’s latest price update
Emergent Biosolutions Inc (NYSE: EBS)’s stock price has plunge by -2.10relation to previous closing price of 11.20. Nevertheless, the company has seen a -3.05% plunge in its stock price over the last five trading sessions. marketbeat.com reported 2024-07-18 that MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Analysts’ Opinion of EBS
Many brokerage firms have already submitted their reports for EBS stocks, with The Benchmark Company repeating the rating for EBS by listing it as a “Buy.” The predicted price for EBS in the upcoming period, according to The Benchmark Company is $5 based on the research report published on March 07, 2024 of the current year 2024.
EBS Trading at 60.31% from the 50-Day Moving Average
After a stumble in the market that brought EBS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.93% of loss for the given period.
Volatility was left at 10.15%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares surge +64.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +143.54% upper at present.
During the last 5 trading sessions, EBS fell by -5.04%, which changed the moving average for the period of 200-days by +259.20% in comparison to the 20-day moving average, which settled at $8.98. In addition, Emergent Biosolutions Inc saw 356.87% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EBS starting from Zoon Kathryn C, who sale 10,000 shares at the price of $6.11 back on Jun 04 ’24. After this action, Zoon Kathryn C now owns 54,482 shares of Emergent Biosolutions Inc, valued at $61,100 using the latest closing price.
Zoon Kathryn C, the Director of Emergent Biosolutions Inc, sale 1,830 shares at $4.61 during a trade that took place back on May 29 ’24, which means that Zoon Kathryn C is holding 64,482 shares at $8,436 based on the most recent closing price.
Stock Fundamentals for EBS
Current profitability levels for the company are sitting at:
- -0.45 for the present operating margin
- 0.38 for the gross margin
The net margin for Emergent Biosolutions Inc stands at -0.48. The total capital return value is set at -0.46. Equity return is now at value -60.56, with -23.78 for asset returns.
Based on Emergent Biosolutions Inc (EBS), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.09. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -5.67.
Currently, EBITDA for the company is -42.9 million with net debt to EBITDA at 9.44. When we switch over and look at the enterprise to sales, we see a ratio of 1.19. The receivables turnover for the company is 5.08for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.08.
Conclusion
To sum up, Emergent Biosolutions Inc (EBS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
